Abstract
Introduction: The aim of the study was to evaluate the influence of estradiol-producing ovarian tumors, including surface epithelial-stromal tumors, on the cervical cytology of postmenopausal women. Methods: This case-controlled study included 160 postmenopausal women who underwent a gynecological surgery between January 2009 and December 2016. The relationship between serum estradiol levels and the maturation index of cervical cytology was examined. Patients with ovarian tumors and a high estradiol level (≥28 pg/mL) constituted the estradiol-producing ovarian tumor group (30 women, including 23 with surface epithelial-stromal tumors). The maturation index of this group was compared with that of the control group (130 women with normal estradiol levels [<28 pg/mL] with either ovarian tumors or uterine tumors). Results: For all patients, the serum estradiol levels were significantly correlated with the maturation index (p < 0.001, r = 0.65). The maturation index of the estradiol-producing ovarian tumor group was significantly higher than that of the control group (0.67 ± 0.21 vs. 0.075 ± 0.16, p < 0.001). The area under the receiver operating characteristic curve for the maturation index was 0.94. The best maturation index cut-off level for estradiol-producing ovarian tumors was 0.20. Using this cut-off, the sensitivity and specificity were 94% and 82%, respectively. Conclusion: Estradiol-producing ovarian tumors influence cervical epithelial maturation in postmenopausal women. An increased maturation index may trigger the early detection of asymptomatic ovarian tumors.
References
1.
National Institutes of Health – National Cancer Institute, Surveillance, Epidemiology and End Results Program
. Statistical summaries: cancer stat fact sheets (ovary) and cancer statistics review (CSR); 1975–2017
[cited Jul 20, 2020]. Available from: http://seer.cancer.gov/statistics/summaries.html.2.
Haroon
S
, Zia
A
, Idrees
R
, Memon
A
, Fatima
S
, Kayani
N
. Clinicopathological spectrum of ovarian sex cord-stromal tumors; 20 Years’ Retrospective Study in a developing country
. J Ovarian Res
. 2013
;6
(1
):87
. .3.
Evans
AT
3rd, Gaffey
TA
, Malkasian
GD
Jr, Annegers
JF
. Clinicopathologic review of 118 granulosa and 82 theca cell tumors
. Obstet Gynecol
. 1980
;55
(2
):231
–8
.4.
Pectasides
D
, Pectasides
E
, Psyrri
A
. Granulosa cell tumor of the ovary
. Cancer Treat Rev
. 2008
;34
(1
):1
–12
. .5.
Burandt
E
, Young
RH
. Thecoma of the ovary: a report of 70 cases emphasizing aspects of its histopathology different from those often portrayed and its differential diagnosis
. Am J Surg Pathol
. 2014
;38
(8
):1023
–32
. .6.
Fox
H
, Agrawal
K
, Langley
FA
. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis
. Cancer
. 1975
;35
(1
):231
–41
. .7.
Stenwig
JT
, Hazekamp
JT
, Beecham
JB
. Granulosa cell tumors of the ovary. A Clinicopathological Study of 118 cases with long- term follow-up
. Gynecol Oncol
. 1979
;7
(2
):136
–52
.8.
Segal
R
, DePetrillo
AD
, Thomas
G
. Clinical review of adult granulosa cell tumors of the ovary
. Gynecol Oncol
. 1995
;56
(3
):338
–44
. .9.
Aiman
J
, Forney
JP
, Parker
CR
Jr. Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women
. Obstet Gynecol
. 1986
;68
(1
):1
–5
.10.
Heinonen
PK
, Koivula
T
, Rajaniemi
H
, Pystynen
P
. Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors
. Gynecol Oncol
. 1986
;25
(1
):1
–10
. .11.
Mählck
CG
, Bäckström
T
, Kjellgren
O
. Plasma level of estradiol in patients with ovarian malignant tumors
. Gynecol Oncol
. 1988
;30
(3
):313
–20
.12.
Matsuoka
A
, Tate
S
, Nishikimi
K
, Ishikawa
H
, Shozu
M
. Elevated serum progesterone levels in postmenopausal women with mucinous ovarian tumors
. Menopause
. 2016
;23
(5
):544
–9
. .13.
Nilsson
K
, Risberg
B
, Heimer
G
. The vaginal epithelium in the postmenopause: cytology, histology and pH as methods of assessment
. Maturitas
. 1995
;21
(1
):51
–6
. .14.
Kurman
RJ
, Carcangiu
ML
, Herrington
CS
, Young
RH
. WHO classification of tumours of female reproductive organs
. 4th ed. Lyon
: International Agency for Research on Cancer
; 2014
.15.
Manonai
J
, Chittacharoen
A
, Theppisai
U
. Effect of estradiol valerate and levonorgestrel on vaginal health
. Eur J Obstet Gynecol Reprod Biol
. 2004
;115
(2
):190
–3
. .16.
Griesser
H
, Skonietzki
S
, Fischer
T
, Fielder
K
, Suesskind
M
. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol
. Maturitas
. 2012
;71
(4
):360
–8
.17.
Pickar
JH
, Amadio
JM
, Hill
JM
, Bernick
BA
, Mirkin
S
. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol
. Menopause
. 2016
;23
(5
):506
–10
. .18.
Cotreau
MM
, Chennathukuzhi
VM
, Harris
HA
, Han
L
, Dorner
AJ
, Apseloff
G
, A Study of 17 Beta-Estradiol-Regulated Genes in the vagina of postmenopausal women with vaginal atrophy
. Maturitas
. 2007
;58
(4
):366
–76
.19.
Tsugawa
K
, Jones
MK
, Sugimachi
K
, Sarfeh
IJ
, Tarnawski
AS
. Biological role of phosphatase PTEN in cancer and tissue injury healing
. Front Biosci
. 2002
;7
:e245
–51
. .20.
Ottolina
J
, Ferrandina
G
, Gadducci
A
, Scollo
P
, Lorusso
D
, Giorda
G
, Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?
Gynecol Oncol
. 2015
;136
(2
):230
–4
.21.
Takai
N
, Kai
K
, Tsuno
A
, Nasu
K
, Kashima
K
, Narahara
H
. Synchronous ovarian endometrioid adenocarcinoma with a functioning stroma and endometrial endometrioid adenocarcinoma by different loss of heterozygosity findings
. Arch Gynecol Obstet
. 2011
;284
(4
):951
–5
. .22.
Matsumura
S
, Ohta
T
, Takahashi
T
, Yamazaki
T
, Takahashi
K
, Kurachi
H
. Non-sex cord-stromal ovarian tumors frequently produce and secrete estrogen in postmenopausal women: impact on bone metabolism and abnormal endometrial histology
. J Clin Endocrinol Metab
. 2013
;98
(7
):2775
–82
. .23.
Ridderheim
M
, Mählck
CG
, Selstam
G
, Stendahl
U
, Bäckström
T
. Steroid production in different parts of malignant and benign ovarian tumors in vitro
. Cancer Res
. 1993
;53
(10 Suppl
):2309
–12
.24.
Kato
N
, Hayasaka
T
, Takeda
J
, Osakabe
M
, Kurachi
H
. Ovarian tumors with functioning stroma: a clinicopathologic study with special reference to serum estrogen level, stromal morphology, and aromatase expression
. Int J Gynecol Pathol
. 2013
;32
(6
):556
–61
. .25.
Tanaka
YO
, Ide
Y
, Nishida
M
, Nishide
K
, Tsunoda
H
, Kajitani
M
, Ovarian tumor with functioning stroma
. Comput Med Imaging Graph
. 2002
;26
(3
):193
–7
.26.
Hattori
Y
, Yamada
S
, Yamamoto
M
, Orisaka
M
, Mizutani
T
, Yoshida
Y
. Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions
. J Ovarian Res
. 2015
;8
:73
. .27.
Miller
S
, Bhasin
N
, Urrego
H
, Moroz
K
, Rowan
BG
, Ramayya
MS
, Genetic and epigenetic alterations of steroidogenic factor 1 in ovarian tumors
. Int J Oncol
. 2013
;42
(2
):627
–34
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
